Nvidia has dominated the AI narrative in the stock market, captivating investors and the media after soaring 2,190% over the ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Polaris Capital Management, an investment management company, released its third quarter 2024 investor letter. A copy of the ...
Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.57 which represents a slight increase of $1.48 or 1.62% from the prior close of $91.09. The stock opened at $90.92 and ...
在激烈的生物医药竞争中,Assembly Biosciences(纳斯达克代码:ASMB)最近传出了振奋人心的消息。该公司专注于开发针对严重病毒性疾病的创新疗法,并于19日宣布获得了巨头吉利德科学(Gilead Sciences)2010万美元的股权投资。这笔投资不仅提升了吉利德对Assembly Bio的持股比例至29.9%,同时还包括1000万美元的加速资金,用于推动新型抗病毒疗法的研发。
“科研圈日报”主要关注科研圈与研究者个体、科研圈与更广阔的社会环境之间的重要互动。点击 这里 可以查看往期内容。· 科学突破《科学》公布 2024 年度十大突破,SpaceX“筷子夹火箭”入选,长效艾滋病预防药物位列榜首图片来源:SpaceX当地时间 ...
Gilead Sciences will no longer provide four HIV medicines for free as part of a patient assistance program starting at the ...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor ...
Shares of Assembly Biosciences (NASDAQ:ASMB) traded higher on Thursday after Gilead Sciences (NASDAQ:GILD) agreed to increase ...
01 吉利德科学公司宣布,美国FDA已授予Trodelvy突破性疗法认定,用于治疗接受铂类化疗后疾病进展的广泛期小细胞肺癌 (ES-SCLC)成人患者。 04 目前,Trodelvy已在超过50个国家和地区获批,用于治疗经治转移性三阴性乳腺癌 ...
Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have gained 15.4% in a year against the industry’s decline of 10.8%. The stock has ...
Gilead Sciences, Inc. has announced that Trodelvy (sacituzumab govitecan-hziy) has received Breakthrough Therapy Designation ...